$EVFM

Evofem Biosciences Inc

  • OTC MARKETS
  • Health Technology
  • Biotechnology
  • Manufacturing
  • Pharmaceutical Preparation Manufacturing

PRICE

$0.4782 -

Last Close

VOLUME

53,992,633

DAY RANGE

0.43 - 0.59

52 WEEK

0 - 0

Join Discuss about EVFM with like-minded investors

OU
@outsider11 #StockTraders.NET
recently

do you see $EVFM making news highs?

79 Replies 12 ๐Ÿ‘ 8 ๐Ÿ”ฅ

SO
@soheil.n #StockTraders.NET
recently

$EVFM - possible macro clear out over 1.5s (no borrows)

106 Replies 7 ๐Ÿ‘ 11 ๐Ÿ”ฅ

profile
@Math #StockTraders.NET
recently

$SIGA $VERU $HTCR $IINN $EVFM main

103 Replies 9 ๐Ÿ‘ 10 ๐Ÿ”ฅ

profile
@dros #droscrew
recently

RECAP 6/29 Unusual Calls: $FSR Aug05 9 C $AGEN Aug 3 C $VALE Jul 15.5 C $LCID Jul 19.5 C $QCOM Oct 165 C $EVFM Jul 1 C $ASHR Sep 36 C $JBLU Jul08 9.5 C

124 Replies 11 ๐Ÿ‘ 13 ๐Ÿ”ฅ

SO
@soheil.n #StockTraders.NET
recently

$EVFm - only got partial fill on the long (Type 4 play)

101 Replies 13 ๐Ÿ‘ 15 ๐Ÿ”ฅ

SO
@soheil.n #StockTraders.NET
recently

done $LI ...missed the add at 38.2 was gonna put stop sell orders but $EVFM long took the attention

76 Replies 7 ๐Ÿ‘ 13 ๐Ÿ”ฅ

profile
@singletary #StockTraders.NET
recently

$evfm $agrx nice gaps

98 Replies 9 ๐Ÿ‘ 12 ๐Ÿ”ฅ

SO
@soheil.n #StockTraders.NET
recently

here it is ..didn't get to AHs > @soheil.n said: $EVFM - high of day clear out incoming? AHs?

118 Replies 6 ๐Ÿ‘ 13 ๐Ÿ”ฅ

SO
@soheil.n #StockTraders.NET
recently

$EVFM - high of day clear out incoming? AHs?

140 Replies 6 ๐Ÿ‘ 15 ๐Ÿ”ฅ

profile
@viking #StockTraders.NET
recently

Upside: -RMED +45% (momentum) -LMNL +44% (momentum following FDA approval for its Biologics License Application for Ryplazim) -USCR +28% (to be acquired by Vulcan Materials for $74.00/shr in cash valued at $1.29B) -QTS +21% (to be acquired by Blackstone at $78.00/shr for a total transaction value of $10B) -BNGO +14% (names Jason Priar as its Chief Commercial Officer) -EVFM +14% (momentum) -MIC +12% (confirms to sell Atlantic Aviation unit for $4.48B in cash and assumed debt and reorganization obligations) -CDXC +11% (ChromaDex and Walmart launch Tru Niagen in 3,800 (from 3K prior) Walmart Stores Across the United States) -GIII +8.1% (earnings, guidance) -BLUE +7.4% (announces the Lifting of FDA Clinical Hold for Sickle Cell Disease and รŸ-Thalassemia Studies) -VERU +5.0% (announces positive data at ASCO) -BIIB +4.7% (Biogen and Bio-Thera announce positive results from Phase 3 study of BAT1806) -NOVN +2.3% (results from Novanโ€™s Exploratory Studies further demonstrate Antimicrobial Effect of NITRICILโ„ข Platform Technology with NVN4100 in Companion Animal Health) -KKR +1.1% (MIC confirms to sell Atlantic Aviation unit for $4.48B in cash and assumed debt and reorganization obligations) Downside: -MOSY -12% (files to sell 1.8M shares at $7.15/shr for a total value of $13M) -PIXY -7.3% (files to sell up to 10.1M shares for holders) -WERN -2.0% (hearing cut at Goldman Sachs to Sell from Neutral) -MSTR -1.2% (to incur $284.5M impairment loss in Q2 due to fluctuations in Bitcoin; files to sell $400M of Senior secured 2028 notes)

81 Replies 13 ๐Ÿ‘ 8 ๐Ÿ”ฅ

profile
@Navneet #droscrew
recently

$EVFM #DD Q4 is their first full Q of earnings of their non hormonal birth control for women. They have 100M cash and 180M mcap. They had a VA order for $7.5M and if they can show they can sell descent amount of product to $10M quarter, it could get the stock price rolling.

140 Replies 14 ๐Ÿ‘ 15 ๐Ÿ”ฅ

Key Metrics

Market Cap

0

Beta

0

Avg. Volume

0

Shares Outstanding

82.45 M

Yield

0%

Public Float

0

Next Earnings Date

2022-11-14

Next Dividend Date

Company Information

Evofem Biosciences, Inc., is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs). The Company's first commercial product, Phexxiยฎ (lactic acid, citric acid and potassium bitartrate), is the first and only hormone-free, prescription vaginal gel approved in the United States for the prevention of pregnancy. The Company is evaluating EVO100 in a Phase 3 clinical trial, 'EVOGUARD,' for the prevention of urogenital Chlamydia trachomatis and Neisseria gonorrhoeae infection in women.

CEO: Saundra Pelletier

Website:

HQ: 12400 High Bluff Dr Ste 600 San Diego, 92130-3077 California

Related News